Castle Biosciences Inc (CSTL) — Capital Reinvestment Ratio

Latest as of June 2026: 0.57x

Castle Biosciences Inc (CSTL) has a Capital Reinvestment Ratio of 0.57x as of June 2026, meaning it reinvests 1% of its operating cash flow ($15.20 Million) in capital expenditures ($8.65 Million). Check tangible equity quality of Castle Biosciences Inc to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

0.57x
Capex / Operating Cash Flow

Operating Cash Flow

$15.20 Million
USD

Capital Expenditures

$8.65 Million
USD

Data as of

Jun 2026
Most recent filing

Castle Biosciences Inc Capital Reinvestment Ratio (2019–2025)

This chart tracks Castle Biosciences Inc's Capital Reinvestment Ratio across 4 annual periods. For the full cash flow conversion analysis, see Castle Biosciences Inc cash conversion from operations.

Annual Capital Reinvestment Ratio for Castle Biosciences Inc (2019–2025)

Year-by-year Capital Reinvestment Ratio for Castle Biosciences Inc from 2019 to 2025. See Castle Biosciences Inc (CSTL) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.

Year Reinvestment Ratio Operating CF (USD) Capital Expenditures YoY Change
2025 0.56x $64.35 Million $36.02 Million ▲ +28.2%
2024 0.44x $64.87 Million $28.33 Million ▼ -9.3%
2020 0.48x $9.87 Million $4.75 Million ▲ +260.6%
2019 0.13x $7.01 Million $937.00K
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow